Literature DB >> 11053096

Treatment of spondyloarthropathies with antibodies against tumour necrosis factor alpha: first clinical and laboratory experiences.

J Braun1, J Xiang, J Brandt, H Maetzel, H Haibel, P Wu, S Kohler, M Rudwaleit, S Siegert, A Radbruch, A Thiel, J Sieper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11053096      PMCID： PMC1766610          DOI： 10.1136/ard.59.suppl_1.i85

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  39 in total

1.  The -308.1 polymorphism in the promoter region of the tumor necrosis factor gene is associated with ankylosing spondylitis independent of HLA-B27.

Authors:  F McGarry; R Walker; R Sturrock; M Field
Journal:  J Rheumatol       Date:  1999-05       Impact factor: 4.666

2.  Infliximab for the treatment of fistulas in patients with Crohn's disease.

Authors:  D H Present; P Rutgeerts; S Targan; S B Hanauer; L Mayer; R A van Hogezand; D K Podolsky; B E Sands; T Braakman; K L DeWoody; T F Schaible; S J van Deventer
Journal:  N Engl J Med       Date:  1999-05-06       Impact factor: 91.245

3.  Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year.

Authors:  A Spoorenberg; K de Vlam; D van der Heijde; E de Klerk; M Dougados; H Mielants; H van der Tempel; M Boers; S van der Linden
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

4.  Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Authors:  R Maini; E W St Clair; F Breedveld; D Furst; J Kalden; M Weisman; J Smolen; P Emery; G Harriman; M Feldmann; P Lipsky
Journal:  Lancet       Date:  1999-12-04       Impact factor: 79.321

5.  Genotyping for disease associated HLA DR beta 1 alleles and the need for early joint surgery in rheumatoid arthritis: a quantitative evaluation.

Authors:  A Crilly; N Maiden; H A Capell; R Madhok
Journal:  Ann Rheum Dis       Date:  1999-02       Impact factor: 19.103

Review 6.  The role of tumor necrosis factor in health and disease.

Authors:  B A Beutler
Journal:  J Rheumatol Suppl       Date:  1999-05

7.  Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.

Authors:  P Charles; M J Elliott; D Davis; A Potter; J R Kalden; C Antoni; F C Breedveld; J S Smolen; G Eberl; K deWoody; M Feldmann; R N Maini
Journal:  J Immunol       Date:  1999-08-01       Impact factor: 5.422

8.  Polymorphism within the tumor necrosis factor alpha (TNF) promoter region in patients with ankylosing spondylitis.

Authors:  E L Kaijzel; B M Brinkman; M V van Krugten; L Smith; T W Huizinga; G M Verjans; F C Breedveld; C L Verweij
Journal:  Hum Immunol       Date:  1999-02       Impact factor: 2.850

9.  Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?

Authors:  A Calin; J P Nakache; A Gueguen; H Zeidler; H Mielants; M Dougados
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

10.  Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy.

Authors:  J Brandt; M Bollow; J Häberle; M Rudwaleit; U Eggens; A Distler; J Sieper; J Braun
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580
View more
  11 in total

1.  Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Authors:  A Boonen; D van der Heijde; J L Severens; A Boendermaker; R Landewé; J Braun; J Brandt; J Sieper; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

2.  Candidate's single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis.

Authors:  Ruxandra Schiotis; Alejandra Sánchez; Alejandro Escudero; Nerea Bartolomé; Magdalena Szczypiorska; Pilar Font; Antonio Martínez; Diego Tejedor; Marta Artieda; Juan Mulero; Anca Buzoianu; Eduardo Collantes-Estévez
Journal:  Rheumatol Int       Date:  2013-12-15       Impact factor: 2.631

Review 3.  Juvenile onset spondyloarthropathies: therapeutic aspects.

Authors:  R Burgos-Vargas
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 4.  Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Authors:  J Braun; J Sieper; M Breban; E Collantes-Estevez; J Davis; R Inman; H Marzo-Ortega; H Mielants
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

5.  Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18-19 January 2002.

Authors:  J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 6.  Structure-modifying capacity of anti-tumour necrosis factor-alpha therapy in ankylosing spondylitis.

Authors:  Filip De Keyser; Dominique Baeten; Filip Van den Bosch; Elli Kruithof; Gust Verbruggen; Herman Mielants; Eric Veys
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Infliximab: in ankylosing spondylitis.

Authors:  Dean M Robinson; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Power Doppler ultrasonography in the evaluation of infliximab treatment for sacroiliitis in patients with ankylosing spondylitis.

Authors:  Yeqing Jiang; Ling Chen; Jiaan Zhu; Qin Xue; Niansong Wang; Yunxia Huang; Fang Liu; Yizhou Hu; Bing Hu
Journal:  Rheumatol Int       Date:  2013-02-06       Impact factor: 2.631

Review 9.  Expanding the armamentarium for the spondyloarthropathies.

Authors:  Paul M Peloso; Jürgen Braun
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

Review 10.  Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review.

Authors:  C Keller; A Webb; J Davis
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.